Brokerages Set Savara Inc (NASDAQ:SVRA) Target Price at $8.83

Savara Inc (NASDAQ:SVRA) has been assigned an average rating of “Moderate Buy” from the six research firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $8.83.

Separately, HC Wainwright restated a “buy” rating and set a $6.00 price target on shares of Savara in a research note on Friday, March 28th.

Hedge Funds Weigh In On Savara

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its stake in shares of Savara by 4.6% during the 4th quarter. Vanguard Group Inc. now owns 8,309,970 shares of the company’s stock valued at $25,512,000 after buying an additional 365,959 shares in the last quarter. SG Americas Securities LLC boosted its holdings in shares of Savara by 14.0% in the fourth quarter. SG Americas Securities LLC now owns 51,589 shares of the company’s stock worth $158,000 after acquiring an additional 6,330 shares during the period. JPMorgan Chase & Co. grew its position in shares of Savara by 23.9% in the third quarter. JPMorgan Chase & Co. now owns 69,490 shares of the company’s stock valued at $295,000 after purchasing an additional 13,420 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Savara by 2.1% during the 4th quarter. Geode Capital Management LLC now owns 2,784,037 shares of the company’s stock valued at $8,549,000 after purchasing an additional 57,187 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Savara by 5.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 963,821 shares of the company’s stock worth $2,959,000 after purchasing an additional 52,204 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

Savara Stock Down 11.2 %

SVRA stock opened at $2.86 on Tuesday. The stock has a market cap of $494.06 million, a P/E ratio of -6.65 and a beta of 0.44. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13. The stock’s fifty day simple moving average is $2.90 and its two-hundred day simple moving average is $3.04. Savara has a 1-year low of $2.26 and a 1-year high of $5.11.

Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). The company had revenue of $0.27 million for the quarter. Analysts expect that Savara will post -0.45 EPS for the current year.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.